Ono paid nearly $60m for Japanese rights to carfilzomib after p2 data, ARQL got $30m Asian deal after phase 1...I'm sure there are others.
Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.